NEXLINA D

NEXLINA D is a fixed-dose combination therapy that addresses type 2 diabetes through two complementary mechanisms. Linagliptin enhances insulin secretion and reduces glucagon levels, while Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they provide a comprehensive approach to glycemic control, helping maintain stable blood glucose levels and supporting overall metabolic health.

COMPOSITION:

• Linagliptin 5 mg + Metformin 500/1000 mg

MODE OF ACTION:

• Linagliptin inhibits DPP-4, enhancing incretin hormones to increase insulin secretion and decrease glucagon release.
• Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.

INDICATIONS:

• Management of type 2 diabetes mellitus in adults with inadequate glycemic control on monotherapy.
• Effective as adjunct therapy to diet and exercise.

DOSAGE:

• Usually 1 tablet twice daily with meals to reduce gastrointestinal discomfort.
• Dose adjustment may be required based on renal function and tolerability.

STORAGE: Store at room temperature below 25ᵒC, in a dry place away from direct sunlight.

DISCLAIMER: This information is intended for medical professionals and registered medical practitioners only. Use of this product should be under the supervision of a registered medical practitioner with a valid prescription.